Management Credibility Analysis
Upcoming Catalysts
Verified event feedCompany profile
No description available
- Chief executive
- Not disclosed
- Headquarters
- 29222 RANCHO VIEJO RD., SAN JUAN CAPISTRANO, CA
- Founded
- Not disclosed
📈 Company Timeline
The Ensign Group, Inc. reported A charter or bylaws change
The Ensign Group, Inc. filed an 8-K covering a charter or bylaws change, supporting financial statements or exhibits.
The Ensign Group, Inc. reported A material agreement
The Ensign Group, Inc. filed an 8-K covering a material agreement, a material financing obligation, Regulation FD disclosure, supporting financial statements or exhibits.
Large-holder ownership filing
A holder reported or amended a beneficial ownership position of more than 5% in The Ensign Group, Inc..
Large-holder ownership filing
A holder reported or amended a beneficial ownership position of more than 5% in The Ensign Group, Inc..
The Ensign Group, Inc. reported Operating or financial results
The Ensign Group, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
Capital Structure & Financial Position
Financial strength and liquidity analysisSource: SEC EDGAR company facts (opens in a new tab) Balance sheet dated
Peer Comparison - Health Care
| Company | Price | Market Cap |
|---|---|---|
| LLY - Eli Lilly and Company |
$1,276.13
Yahoo Finance |
$1.20T |
| JNJ - Johnson & Johnson |
$256.74
Yahoo Finance |
$618.71B |
| ABBV - AbbVie Inc. |
$284.80
Yahoo Finance |
$503.28B |
| UNH - UnitedHealth Group Incorporated |
$418.43
Yahoo Finance |
$375.58B |
| MRK - Merck & Co., Inc. |
$148.55
Yahoo Finance |
$366.50B |
📋 Corporate Actions
Recent and upcoming corporate eventsFinancials
Financial statements and key metrics analysis| Quarter | Revenue (USD) | Operating income | Net income | Diluted EPS (USD) | Filed |
|---|---|---|---|---|---|
| Q2 2026 | $1.43B | $122.50M | $99.74M | $1.68 | 10-Q · 27 Jul 2026 |
| Q1 2026 | $1.38B | $124.85M | $99.67M | $1.67 | 10-Q · 30 Apr 2026 |
| Q4 2025 | $1.35B | $123.81M | $95.45M | Unavailable | 10-K · 4 Feb 2026 |
| Q3 2025 | $1.29B | $96.22M | $83.84M | $1.42 | 10-Q · 3 Nov 2025 |
| Q2 2025 | $1.22B | $103.90M | $84.40M | $1.44 | 10-Q · 24 Jul 2025 |
| Q1 2025 | $1.17B | $101.37M | $80.28M | $1.37 | 10-Q · 30 Apr 2026 |
Analyst Consensus
Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 210.00–228.00 Ratings are third-party opinions, not advice.
💰 Upcoming Dividends
Next dividend paymentsGuidance Evolution
💼 Director Transactions
Recent insider activityTop Shareholders
Source: Nasdaq institutional holdings (opens in a new tab) Observed · 1 day ago